Spoken Alpha
MAXCYTE, INC.
MaxCyte provides cell engineering platform technologies for developing cell and gene therapies. The company's proprietary Flow Electroporation technology enables biopharmaceutical companies, academic institutions, and research organizations to deliver genetic material and proteins into cells for therapeutic development and manufacturing.
MAXCYTE, INC is a Healthcare company operating in Medical Devices with a $119.7M market cap.
Most recent reported earnings: Q3 FY2026 (Nov 10, 2026).
20 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Disclosures
Transcripts
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for MXCT.
$ curl https://api.spokenalpha.com/v1/companies/MXCTFAQ
Spoken Alpha indexes MXCT's earnings call transcripts at https://spokenalpha.com/companies/MXCT. Each call links to attributed speakers and parsed analyst Q&A.
MAXCYTE, INC. (MXCT) held its most recent earnings call on 2026-05-12, covering fiscal Q1 2026.
MAXCYTE, INC. (MXCT) operates in the Healthcare sector (Medical Devices industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 2026-11-10 | — | $-0.08 | — | — | — | — | EODHD |
| Q2 FY2026 | 2026-08-11 | $-0.08 | $-0.12 | +33.3% | $7.3M | — | — | EODHD |
| Q1 FY2026 | 2026-05-12 | $-0.04 | $-0.07 | +31.7% | $9.7M | — | — | EODHD |
| Q4 FY2025 | 2026-03-23 | $-0.06 | $-0.08 | +25.0% | $7.3M | — | — | EODHD |
| Q3 FY2025 | 2025-11-11 | $-0.09 | $-0.10 | +10.0% | $6.8M | — | — | EODHD |
| Q2 FY2025 | 2025-08-05 | $-0.12 | $-0.10 | -20.0% | $8.5M | — | — | EODHD |
| Q1 FY2025 | 2025-05-06 | $-0.10 | $-0.10 | 0.0% | $10.4M | — | — | EODHD |
| Q4 FY2024 | 2025-03-10 | $-0.10 | $-0.12 | +16.7% | $8.7M | — | — | EODHD |
| Q3 FY2024 | 2024-11-05 | $-0.11 | $-0.12 | +8.3% | $8.2M | — | — | EODHD |
| Q2 FY2024 | 2024-08-05 | $-0.09 | $-0.13 | +30.8% | $10.4M | — | — | EODHD |
| Q1 FY2024 | 2024-05-06 | $-0.09 | $-0.13 | +30.8% | $11.3M | — | — | EODHD |
| Q4 FY2023 | 2024-03-11 | $-0.05 | $-0.07 | +28.6% | $15.7M | — | — | EODHD |
| Q3 FY2023 | 2023-11-07 | $-0.11 | $-0.10 | -10.0% | $8.0M | — | — | EODHD |
| Q2 FY2023 | 2023-08-08 | $-0.10 | $-0.10 | 0.0% | $9.0M | — | — | EODHD |
| Q1 FY2023 | 2023-05-09 | $-0.11 | $-0.11 | 0.0% | $8.6M | — | — | EODHD |
| Q4 FY2022 | 2023-03-14 | $-0.05 | $-0.07 | +28.6% | $12.4M | — | — | EODHD |
| Q3 FY2022 | 2022-11-08 | $-0.06 | $-0.08 | +25.0% | $10.6M | — | — | EODHD |
| Q2 FY2022 | 2022-08-09 | $-0.08 | $-0.07 | -14.3% | $9.6M | — | — | EODHD |
| Q1 FY2022 | 2022-05-08 | $-0.04 | $-0.07 | +42.9% | $11.6M | — | — | EODHD |
| Q4 FY2021 | 2022-03-21 | $-0.05 | $-0.05 | 0.0% | $10.2M | — | — | EODHD |
Source: EODHD. MXCT reported actuals as published; sparse fields render as —.